Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Asherman's SyndromeEndometrium; Atrophy, Cervix
Interventions
BIOLOGICAL

Bone Marrow CD133+ Stem Cell Transplantation

"1. Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.~2. BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.~ The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.~3. CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization~4. Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients~5. Hysteroscopy will be performed 2-3 months after stem cell transplantation~6. Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation"

Trial Locations (2)

46010

Hospital Clinico y Universitario de Valencia, Valencia

46015

Instituto Valenciano Infertilidad, Valencia

All Listed Sponsors
collaborator

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER

lead

Instituto Valenciano de Infertilidad, IVI VALENCIA

OTHER

NCT02144987 - Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy | Biotech Hunter | Biotech Hunter